Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | CASP9 | P55211 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 2/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646635 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29384302 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL26071633 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL20257211 | 0.93 | REN (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29825423 | 0.93 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310885 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL15012737 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310886 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034510-A1 | SYSTEMS, DEVICES, AND METHODS FOR BIOLOGICAL MATERIAL RESTORATION AND/OR CRYOPRESERVATION | OREGON STATE UNIVERSITY (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4185388-A1 | A COMBINATION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA | Genmab B.V. (NL) | 2023-05-31 | — | — | EP | disclosed |
| EP-3966241-A1 | DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER | Genmab B.V. (NL) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022018294-A1 | A COMBINATION OF ANTI-DR5 ANTIBODIES AND AN IMMUNOMODULATORY IMIDE DRUG FOR USE IN TREATING MULTIPLE MYELOMA | GENMAB B.V. (NL) | 2022-01-27 | — | — | WO | disclosed |
| US-20220017944-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-01-20 | — | — | US | disclosed |